FABP3 and early-onset autosomal dominant Alzheimer disease: Furthermore, the increased presence of FABP3 in the plasma of Parkinson’s disease patients indicated its potential benefit in predicting disease risk and discriminating from other α-synucleinopathies and Alzheimer’s disease, using multi-marker analyses.